RU2006109010A - Новый состав - Google Patents
Новый состав Download PDFInfo
- Publication number
- RU2006109010A RU2006109010A RU2006109010/15A RU2006109010A RU2006109010A RU 2006109010 A RU2006109010 A RU 2006109010A RU 2006109010/15 A RU2006109010/15 A RU 2006109010/15A RU 2006109010 A RU2006109010 A RU 2006109010A RU 2006109010 A RU2006109010 A RU 2006109010A
- Authority
- RU
- Russia
- Prior art keywords
- dosage form
- ropinirole
- form according
- hours
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims 33
- 239000002552 dosage form Substances 0.000 claims 31
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 24
- 229960001879 ropinirole Drugs 0.000 claims 19
- XDXHAEQXIBQUEZ-UHFFFAOYSA-N Ropinirole hydrochloride Chemical compound Cl.CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 XDXHAEQXIBQUEZ-UHFFFAOYSA-N 0.000 claims 14
- 229960002349 ropinirole hydrochloride Drugs 0.000 claims 14
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 12
- 235000019359 magnesium stearate Nutrition 0.000 claims 12
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 11
- 229960001021 lactose monohydrate Drugs 0.000 claims 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 11
- 229940057948 magnesium stearate Drugs 0.000 claims 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 7
- 239000006186 oral dosage form Substances 0.000 claims 7
- 238000004090 dissolution Methods 0.000 claims 5
- 208000005793 Restless legs syndrome Diseases 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 235000010443 alginic acid Nutrition 0.000 claims 3
- 229920000615 alginic acid Polymers 0.000 claims 3
- 238000013270 controlled release Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- 239000005913 Maltodextrin Substances 0.000 claims 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000000783 alginic acid Substances 0.000 claims 2
- 229960001126 alginic acid Drugs 0.000 claims 2
- 150000004781 alginic acids Chemical class 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000008109 sodium starch glycolate Substances 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 239000000454 talc Substances 0.000 claims 2
- 229910052623 talc Inorganic materials 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 239000012062 aqueous buffer Substances 0.000 claims 1
- 239000011805 ball Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920003086 cellulose ether Polymers 0.000 claims 1
- -1 ceratonium Polymers 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004667 ethyl cellulose Drugs 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 229940075507 glyceryl monostearate Drugs 0.000 claims 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 239000004574 high-performance concrete Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229960001708 magnesium carbonate Drugs 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- 239000000391 magnesium silicate Substances 0.000 claims 1
- 235000019792 magnesium silicate Nutrition 0.000 claims 1
- 229910052919 magnesium silicate Inorganic materials 0.000 claims 1
- 229940091250 magnesium supplement Drugs 0.000 claims 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 229960002160 maltose Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims 1
- 235000010234 sodium benzoate Nutrition 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0319874.4 | 2003-08-22 | ||
| GBGB0319874.4A GB0319874D0 (en) | 2003-08-22 | 2003-08-22 | Novel formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006109010A true RU2006109010A (ru) | 2006-08-10 |
Family
ID=28460214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006109010/15A RU2006109010A (ru) | 2003-08-22 | 2004-08-19 | Новый состав |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070059365A1 (enExample) |
| EP (1) | EP1656118A2 (enExample) |
| JP (1) | JP2007503414A (enExample) |
| KR (1) | KR20060120596A (enExample) |
| CN (1) | CN1838945A (enExample) |
| AR (1) | AR045289A1 (enExample) |
| AU (1) | AU2004266072A1 (enExample) |
| BR (1) | BRPI0413632A (enExample) |
| CA (1) | CA2536414A1 (enExample) |
| GB (1) | GB0319874D0 (enExample) |
| IL (1) | IL173440A0 (enExample) |
| IS (1) | IS8352A (enExample) |
| MA (1) | MA27998A1 (enExample) |
| MX (1) | MXPA06002023A (enExample) |
| NO (1) | NO20061291L (enExample) |
| RU (1) | RU2006109010A (enExample) |
| TW (1) | TW200517107A (enExample) |
| WO (1) | WO2005018605A2 (enExample) |
| ZA (1) | ZA200600719B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080078075A (ko) | 2005-12-20 | 2008-08-26 | 세레우사이언스 아베 | 하지 불안 증후군의 치료 및 진단을 위한 방법 및 조성물 |
| US20100136125A1 (en) * | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
| EP2022496A1 (en) * | 2007-07-16 | 2009-02-11 | Ranbaxy Laboratories Limited | Stable ropinirole compositions |
| WO2009023761A2 (en) * | 2007-08-14 | 2009-02-19 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising ropinirole |
| US20090076124A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched ropinirole |
| WO2009078034A2 (en) * | 2007-11-26 | 2009-06-25 | Rubicon Research Private Limited | Oral disintegrating tablets of ropinirole hydrochloride |
| CN101574341B (zh) * | 2008-05-05 | 2012-12-19 | 北京德众万全医药科技有限公司 | 一种罗匹尼罗的口服固体药物组合物 |
| SI22849A (sl) * | 2008-08-01 | 2010-02-26 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Ropinirolni pripravek |
| WO2010015911A1 (en) * | 2008-08-06 | 2010-02-11 | Torrent Pharmaceuticals Limited | Sustained release pharmaceutical compositions of ropinirole and process for preparation thereof |
| WO2010023693A2 (en) * | 2008-09-01 | 2010-03-04 | Lupin Limited | Novel controlled release compositions of ropinirole |
| CA2738414C (en) | 2008-09-29 | 2014-05-27 | Wockhardt Research Centre | Extended release dosage form of ropinirole |
| WO2010044108A2 (en) | 2008-10-17 | 2010-04-22 | Rubicon Research Private Limited | Controlled release formulations of ropinirole |
| MX381895B (es) * | 2009-02-13 | 2025-03-13 | Romark Laboratories Lc | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. |
| WO2011032416A1 (zh) * | 2009-09-19 | 2011-03-24 | 浙江华海药业股份有限公司 | 含有多巴胺受体激动剂的药物组合物 |
| KR101068476B1 (ko) * | 2009-12-29 | 2011-09-28 | 환인제약 주식회사 | 로피니롤 경구 투여용 서방성 제제 |
| GR1007629B (el) * | 2011-07-13 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα ελεγχομενης αποδεσμευσης ενος μη εργολινικου αγωνιστη της ντοπαμινης |
| EP2806861A1 (en) * | 2012-01-23 | 2014-12-03 | Ranbaxy Laboratories Limited | In-situ multilayered tablet technology |
| ITFI20130189A1 (it) * | 2013-08-05 | 2015-02-06 | Valpharma Internat S P A | Una composizione farmaceutica contenente ropinirolo hcl somministrabile per via orale e metodo di produzione. |
| US9463889B2 (en) * | 2013-10-25 | 2016-10-11 | Medtronic, Inc. | Prefilled reservoir apparatus for ambulatory infusion device |
| CN104188931B (zh) * | 2014-08-25 | 2017-06-16 | 泰州越洋医药开发有限公司 | 一种盐酸罗匹尼罗固体口服控释片剂及其制备方法 |
| CN104473893A (zh) * | 2014-11-21 | 2015-04-01 | 哈尔滨圣吉药业股份有限公司 | 一种盐酸罗匹尼罗缓释片及其制备方法 |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| EP4066829A4 (en) * | 2019-11-26 | 2023-12-27 | Hisamitsu Pharmaceutical Co., Inc. | METHOD FOR IMPROVING THE HOLDING POWER OF AN ADHESIVE LAYER IN A ROPINIROL-CONTAINING TRANSDERMAL PATCH AND ROPINIROL-CONTAINING TRANSDERMAL PATCH WITH IMPROVED HOLDING POWER |
| CN114727965B (zh) * | 2019-12-23 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂药物组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1188212B (it) * | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| IT1237904B (it) * | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
| IT1265240B1 (it) * | 1993-11-30 | 1996-10-31 | Ekita Investments Nv | Compressa farmaceutica a rilascio controllato, di forma lenticolare |
| US20010029262A1 (en) * | 1998-06-29 | 2001-10-11 | Sethi Kapil Dev | Method of treatment or prophylaxis |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| GB0125088D0 (en) * | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| WO2004000263A1 (en) * | 2002-06-25 | 2003-12-31 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
-
2003
- 2003-08-22 GB GBGB0319874.4A patent/GB0319874D0/en not_active Ceased
-
2004
- 2004-08-19 AU AU2004266072A patent/AU2004266072A1/en not_active Abandoned
- 2004-08-19 JP JP2006524307A patent/JP2007503414A/ja active Pending
- 2004-08-19 EP EP04764339A patent/EP1656118A2/en not_active Withdrawn
- 2004-08-19 CN CNA2004800241337A patent/CN1838945A/zh active Pending
- 2004-08-19 KR KR1020067003501A patent/KR20060120596A/ko not_active Withdrawn
- 2004-08-19 BR BRPI0413632-2A patent/BRPI0413632A/pt not_active IP Right Cessation
- 2004-08-19 RU RU2006109010/15A patent/RU2006109010A/ru not_active Application Discontinuation
- 2004-08-19 WO PCT/EP2004/009356 patent/WO2005018605A2/en not_active Ceased
- 2004-08-19 US US10/569,398 patent/US20070059365A1/en not_active Abandoned
- 2004-08-19 CA CA002536414A patent/CA2536414A1/en not_active Abandoned
- 2004-08-19 MX MXPA06002023A patent/MXPA06002023A/es not_active Application Discontinuation
- 2004-08-20 TW TW093125047A patent/TW200517107A/zh unknown
- 2004-08-20 AR ARP040102989A patent/AR045289A1/es not_active Application Discontinuation
-
2006
- 2006-01-25 ZA ZA200600719A patent/ZA200600719B/xx unknown
- 2006-01-30 IL IL173440A patent/IL173440A0/en unknown
- 2006-02-17 MA MA28819A patent/MA27998A1/fr unknown
- 2006-03-14 IS IS8352A patent/IS8352A/is unknown
- 2006-03-21 NO NO20061291A patent/NO20061291L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200600719B (en) | 2007-03-28 |
| TW200517107A (en) | 2005-06-01 |
| EP1656118A2 (en) | 2006-05-17 |
| WO2005018605A3 (en) | 2005-11-03 |
| CN1838945A (zh) | 2006-09-27 |
| BRPI0413632A (pt) | 2006-10-17 |
| KR20060120596A (ko) | 2006-11-27 |
| GB0319874D0 (en) | 2003-09-24 |
| JP2007503414A (ja) | 2007-02-22 |
| IS8352A (is) | 2006-03-14 |
| MXPA06002023A (es) | 2006-05-17 |
| US20070059365A1 (en) | 2007-03-15 |
| CA2536414A1 (en) | 2005-03-03 |
| WO2005018605A2 (en) | 2005-03-03 |
| MA27998A1 (fr) | 2006-07-03 |
| NO20061291L (no) | 2006-05-16 |
| IL173440A0 (en) | 2006-06-11 |
| AR045289A1 (es) | 2005-10-19 |
| AU2004266072A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007503414A5 (enExample) | ||
| JP5816091B2 (ja) | ナトリウムオキシベートの即時放出投薬形態 | |
| KR101699912B1 (ko) | 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제 | |
| JP4969586B2 (ja) | マルチプルユニット型徐放性経口製剤およびその製造方法 | |
| US20020115718A1 (en) | Divalproex sodium tablets | |
| RU2012106139A (ru) | Лекарственные формы цитрата железа (iii) | |
| US20070059365A1 (en) | Novel formulation of ropinirole | |
| US20070104785A1 (en) | Tablets of linezolid form iii and processes for their preparation | |
| EP2496217B1 (en) | Direct compression tablets of otilonium | |
| JP5775085B2 (ja) | ｃ−ＭＥＴキナーゼ阻害剤の製剤 | |
| JP2019529570A (ja) | ミドドリンの組成物およびその使用方法 | |
| WO2010026467A2 (en) | Controlled release dosage form of high solubility active ingredient | |
| WO2011135581A2 (en) | Pharmaceutical compositions of dronedarone | |
| US20110086102A1 (en) | Delayed release compositions | |
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| EP2959889A1 (en) | Orally disintegrating formulations of loxoprofen | |
| JP7585043B2 (ja) | レナリドミドを含む医薬組成物 | |
| EP4061370A1 (en) | A pellet composition comprising propiverine or a pharmaceutically acceptable salt thereof | |
| WO2024165966A1 (en) | Gastroretentive extended release compositions of riociguat | |
| CA2967645A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| WO2017037645A1 (en) | Stable pharmaceutical formulations of teriflunomide | |
| JP2024503689A5 (enExample) | ||
| TH77775A (th) | สารผสมตามสูตรชนิดใหม่ | |
| JP2009525953A (ja) | ジバルプロ酸及びその誘導体の徐放性製剤 | |
| WO2011046546A1 (en) | Delayed release compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20081216 |